Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 13, 2013 - Issue 2: Monoclonal Antibodies
Submit an article Journal homepage
1,535
Views
13
CrossRef citations to date
0
Altmetric
Editorial

Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure?

Carlo BuonerbaUniversity Federico II, Genitourinary Cancer Section, Medical Oncology Division, Department of Endocrinology and Oncology, Via Pansini, 5 80131 Naples, Italy+39 0817463661; +39 0817463661; [email protected]
, MD,
Michele CaragliaSecond University of Naples, Department of Biochemistry and Biophysics, Naples, Italy
, MD PhD,
Simona MalgieriUniversity Federico II, Genitourinary Cancer Section, Medical Oncology Division, Department of Endocrinology and Oncology, Via Pansini, 5 80131 Naples, Italy+39 0817463661; +39 0817463661; [email protected]
, MD,
Francesco PerriNational Tumor Institute of Naples-Head and Neck Medical Oncology Unit, Naples, Italy
, MD,
Davide BossoUniversity Federico II, Genitourinary Cancer Section, Medical Oncology Division, Department of Endocrinology and Oncology, Via Pansini, 5 80131 Naples, Italy+39 0817463661; +39 0817463661; [email protected]
, MD,
Piera FedericoUniversity Federico II, Genitourinary Cancer Section, Medical Oncology Division, Department of Endocrinology and Oncology, Via Pansini, 5 80131 Naples, Italy+39 0817463661; +39 0817463661; [email protected]
, MD,
Matteo FerroUniversity Federico II, Genitourinary Cancer Section, Medical Oncology Division, Department of Endocrinology and Oncology, Via Pansini, 5 80131 Naples, Italy+39 0817463661; +39 0817463661; [email protected]
, MD,
Mimma RizzoCardarelli Hospital of Naples, Oncology Division, Naples, Italy
, MD,
Giovannella PalmieriUniversity Federico II, Genitourinary Cancer Section, Medical Oncology Division, Department of Endocrinology and Oncology, Via Pansini, 5 80131 Naples, Italy+39 0817463661; +39 0817463661; [email protected]
, MD &
Giuseppe Di LorenzoUniversity Federico II, Genitourinary Cancer Section, Medical Oncology Division, Department of Endocrinology and Oncology, Via Pansini, 5 80131 Naples, Italy+39 0817463661; +39 0817463661; [email protected]
, MD PhD show all
Pages 149-151 | Published online: 25 Dec 2012

Bibliography

  • Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12(20 Pt 2):6243s-9s
  • Rubin P, Brasacchio R, Katz A. Solitary metastases: illusion versus reality. Semin Radiat Oncol 2006;16(2):120-30
  • Suva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 2011;7:208-18
  • Caraglia M, Marra M, Naviglio S, Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin Pharmacother 2010;11(1):141-54
  • Stopeck AT, Lipton A, Body JJ, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28(35):5132-9
  • Fizazi K, Carducci M, Smith M, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22
  • Ford JA, Jones R, Elders A, Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. Eur J Cancer 2012; [Epub ahead of print]
  • Henry DH, Costa L, Goldwasser F, Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29(9):1125-32
  • FDA labeling information of denosumab. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125320s0054lbl.pdf [Accessed on 4 September 2012]
  • Block GA, Bone HG, Fang L, A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012;27(7):1471-9
  • Cozzolino M, Gallieni M, Brancaccio D, Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure. J Nephrol 2006;19(5):566-77
  • Goodman WG, Coburn JW. The use of 1,25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med 1992;43:227-37
  • Negri AL. Association of oral calcitriol with improved survival in non-dialysed and dialysed patients with CKD. Nephrol Dial Transplant 2009;24(2):341-4
  • Cochran M, Coates PT, Morris HA. The effect of calcitriol on fasting urine calcium loss and renal tubular reabsorption of calcium in patients with mild renal failure–actions of a permissive hormone. Clin Nephrol. 2005;64(2):98-102
  • Janus N, Le Tourneau C, Launay-Vacher V, Renal insufficiency in bone metastasis cancer patients: prevalence and implications on anticancer drugs management, subgroup analysis of the IRMA study. J Clin Oncol 2007;25(Suppl):9121

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.